Vysis adds foetal cell diagnostics patents
This article was originally published in Clinica
Executive Summary
Vysis has bought out all of Aprogenex' patents for birth defect testing based on mRNA assays of foetal cells in maternal blood. Vysis, of Downers Grove, Illinois, hopes to be the first company to bring a foetal cell diagnostic product to market. It says the method may one day become the standard way of pre-natal testing for chromosomal abnormalities.